関連する実験動画

Updated: Jun 23, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

アルツハイマー病における腸内コレシストキニン: マウスモデルにおける様々な疾患段階における早期の脆弱性と救助効果

Yixuan Sui1, Nan Zhang2, Xi Chen1,3

  • 1Department of Neuroscience, City University of Hong Kong, 1A-401, 4/F, Block 1, To Yuen Building, 31 To Yuen Street, Kowloon, Hong Kong, China.

Cellular and molecular neurobiology
|February 14, 2026
PubMed
まとめ

コレチストキニン (CCK) のダウンレギュレーションは,アルツハイマー病 (AD) の初期の兆候です. CCK-B受容体アゴニストは,ADのすべての段階における認知およびシナプス欠陥の治療において有望であることが示されています.

キーワード:
アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,コレチストキニンはコレチストキニンです.薬物開発 薬物開発エントロリン内皮質 (Entorhinal cortex) とは,脳内皮質 (Entorhinal cortex) とは,脳内皮質 (Entorhinal cortex) とは,脳内皮質 (Entorhinal cortex) とは,学習と記憶について

さらに関連する動画

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...